Using a transgenic AD mouse model and cultured human neural cells, earlier studies demonstrated that BDNF reduced amyloidogenic processing of APP and production of toxic Aβ peptides by a mechanism that involves increased α-secretase processing of APP to liberate sAPPα [62]. Here, APP is linked to Alzheimer disease.